Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study - Gadgeel, SM; Gandhi, L; Riely, GJ (Lancet Oncol, 2014)
et al.